Primary thromboprophylaxis in a patient with type 3 von Willebrand disease and severe COVID-19 infection

Haemophilia. 2021 Jul;27(4):e517-e519. doi: 10.1111/hae.14252. Epub 2021 Jan 11.

Authors

Anshul Vagrecha^{1

2}, Joseph Stanco¹, Sumreen Majeed³, Peter Kouides⁴, Suchitra S Acharya^{1

2}

Affiliations

¹ Division of Hematology/Oncology and Cellular Therapy, Department of Pediatrics, Cohen Children's Medical Center, New Hyde Park, NY, USA.
² Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
³ Northwell Health Cancer Institute, Imbert Cancer Center, Bay Shore, NY, USA.
⁴ Mary M. Gooley Hemophilia Center, University of Rochester School of Medicine, Rochester, NY, USA.

No abstract available

Keywords: COVID-19; LMWH; anticoagulation; bleeding disorder; thromboprophylaxis; von Willebrand disease.

Publication types

Case Reports
Letter

MeSH terms

Aged
Anticoagulants / therapeutic use*
COVID-19 / complications*
COVID-19 / therapy
Disease Management
Female
Heparin, Low-Molecular-Weight / therapeutic use*
Humans
SARS-CoV-2 / isolation & purification
Thrombosis / etiology
Thrombosis / prevention & control*
Venous Thromboembolism / etiology
Venous Thromboembolism / prevention & control*
von Willebrand Disease, Type 3 / complications*
von Willebrand Disease, Type 3 / therapy

Substances

Anticoagulants
Heparin, Low-Molecular-Weight